Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 73

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 73
---
 and efficient than mRNA vaccines and provide more durable, longer-lasting protection. |

| - | Provide                                                                                   
 broader cross-immunity to protect against new virus variants. Possible intranasal form is 
 expected to generate a significant and lasting immune response.                           |

| - | Expected                                                                                      
 to boost the immune system of people vaccinated with other vaccines as well as to effectively 
 stop the spread of the pandemic.                                                              |

Recent animal studies conducted by Prof. Barenholz demonstrated that the new LPLT technology induced strong immune response and high levels of antibodies. The platform uses a recombinant technology that is suggested to protect against transmission of a specific virus using 2 different protein sequences encapsulated in novel lipid nanoparticles.

The platform is expected to efficiently interrupt the transmission chain and stop the rapid and deadly spread, in cases of bird flu, Ebola and others. High mucosal immunity demonstrated in animal experiments may be critical in fighting Coronavirus mutations and other deadly viruses.

LPLT technology may potentially have several advantages over the current methods of protein delivery. Firstly, this drug-delivery technology is designed to protect the proteins from degradation and clearance by the immune system or the liver, thus increasing their half-life and reducing the frequency and dose of administration. Secondly, it can improve the biodistribution and accumulation of the proteins at the desired sites of action, such as inflamed tissues, or infected cells, thus increasing their efficacy and reducing their side effects.

The Company is currently examining the commercial potential of the novel immunization approach.

LPLT protein delivery technology is patent protected.

Vaccines: Sphingolipids Polyalkylamines Conjugates for Vaccination

| Status  |     | Country |     | Application Date |     | Publication Number |     | Patent Date    |     | Patent Number |     | Expiry Date       |
| Granted |     | US      |     | May 5, 2006      |     | 2006/0252717       |     | March 18, 2014 |     |     8,673,285 |     | February 18, 2027 |
| Granted |     | US      |     | February 2, 2006 |     | 2006/0171956       |     | March 5, 2011  |     |     7,906,122 |     | July 16, 2025     |

In addition, we are planning to submit new patent applications for the delivery of specific proteins targeting chosen viruses.